Brief: Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications
18/02/2026 14:02
Feb 18 (Reuters) - Theriva Biologics Inc TOVX.A: THERIVA™ BIOLOGICS LICENSES SYN-020 TO RASAYANA THERAPEUTICS FOR MULTIPLE INDICATIONS THERIVA BIOLOGICS INC: RECEIVED $300,000 UPFRONT PAYMENT AT SIGNING & ELIGIBLE FOR UP TO $38M IN MILESTONE PAYMENTS Source text: ID:nGNE41C06S Further company coverage: TOVX.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theriva Biologics
See all newsTheriva Biologics Q2 net loss narrows on lower R&D costs, expenses
Brief: Theriva™ Biologics Announces Upcoming Presentation Of Additional Data From The Virage Phase 2B Clinical Trial Of Vcn-01 In Metastatic Pancreatic Cancer At Aacr 2026 Annual Meeting
Brief: Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications
Brief: Theriva Biologics Implements 32% Workforce Reduction - SEC Filing
Brief: Theriva™ Biologics Announces Presentation Of Data From Vcn-01 Retinoblastoma Phase 1 Clinical Trial At Asco 2025